We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for polatuzumab vedotin (Roche Products Pty Limited)
Active ingredients
polatuzumab vedotin
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Polatuzumab vedotin in combination with bendamustine and rituximab is indicated for the treatment of previously treated adult patients with diffuse large B-cell lymphoma who are not candidates for hematopoietic stem cell transplant.
Therapeutic area
Haematology